Longevity medicine is having a moment. Clinics are opening in every major city, promising to extend your healthspan, reverse your biological age, and optimize your cellular function. The language is seductive. The price tags are steep. And the evidence behind most of it is thin.

This is not an anti-longevity polemic. Some of the science is genuinely exciting. But the gap between what is being researched and what is being sold is enormous — and patients deserve to know which is which.

What the research actually shows

The science of aging has made remarkable progress in the last two decades. Several mechanisms that drive aging are now understood at a molecular level: telomere shortening, mitochondrial dysfunction, cellular senescence, epigenetic drift, stem cell exhaustion, and chronic low-grade inflammation. This is real science, published in top journals, advancing rapidly.

The problem is the leap from understanding mechanisms to having interventions that work in humans. That leap has been made for very few things:

  • Caloric restriction: In the CALERIE trial, a 25% restriction target (about 12% achieved) over 2 years slowed the pace of aging measured by DunedinPACE by a modest 2–3%; other clocks (PhenoAge, GrimAge) did not change. Among the strongest interventional evidence in humans — but a biomarker, not a clinical outcome.
  • Exercise: Both cardiovascular and resistance training are consistently associated with slower decline across multiple markers. Higher fitness tracks with lower mortality, with no upper limit of benefit observed in a large cohort.
  • Sleep: Adequate sleep duration and quality are independently associated with slower aging and lower all-cause mortality.
  • Not smoking, and drinking little or no alcohol: The basics remain the most powerful longevity interventions we have (see why moderate drinking is not protective).

Notice what is on this list. It is the same advice your grandmother gave you. Longevity science, for all its sophistication, has mostly confirmed what was already known — and added precision about why it works at a cellular level.

What's being sold vs. what's been proven

Now compare that evidence base to what longevity clinics typically offer:

  • NAD+ infusions: No human RCT showing clinical benefit. Animal data is interesting. Cost: $500–2,000 per session.
  • Telomere length testing: High measurement variability. No intervention proven to lengthen telomeres meaningfully. Not actionable.
  • Peptide therapy (BPC-157, thymosin): Almost entirely based on animal studies and case reports. No FDA approval. Unknown long-term safety.
  • Hyperbaric oxygen: Evidence for wound healing and decompression sickness. Evidence for "anti-aging": a single small uncontrolled study (35 participants enrolled) measuring blood-cell markers, not clinical outcomes.
  • Exosome therapy: Theoretical promise. Zero randomized trials. The FDA has issued warnings about unapproved exosome products.

The marketing pattern

Most longevity interventions follow the same script: a plausible mechanism, promising animal data, one or two tiny human studies, and then — before the evidence is anywhere near sufficient — aggressive direct-to-consumer marketing at premium prices. By the time large trials are completed (if they ever are), millions of patients have already paid.

How to judge emerging longevity tests

Not everything new is hype. A reasonable minimum threshold for an emerging test is: published validation data, at least one interventional study, and a clear statement of its limitations. A small number of tests come close to meeting it:

  • DunedinPACE: Developed in the observational Dunedin cohort; in CALERIE it was the only clock that responded to the intervention, modestly. It estimates how fast you are aging right now — whether changing it improves health outcomes is unknown.
  • GRAIL Galleri: Multi-cancer early detection via cfDNA. About 99.5% specificity, but it detected only about a third of cancers in the NHS-Galleri trial (over 140,000 participants), whose 2026 results showed fewer stage IV cancers but no reduction in stage III–IV cancers overall, the main goal. Not guideline-endorsed; consider only with thorough counseling.
  • Omega-3 Index: Measures EPA+DHA in red blood cells. In observational studies, levels ≥8% are associated with lower sudden cardiac death risk. Modifiable through diet and supplementation.

Even these belong in the category "emerging", not "established". If a provider presents such tests as settled science, or bundles them into a standard check-up in place of markers with strong guideline backing, that is a warning sign. Good questions to ask: What outcome does this test predict? Has acting on it been shown to improve anything? What will be done differently depending on the result?

A balanced view of longevity

Longevity science may eventually deliver transformative interventions. Right now, however, the most powerful longevity tools available are fitness, nutrition, sleep, metabolic health, and early detection of the diseases that actually kill people. A sensible prevention strategy is built around those — with emerging science treated as an optional, clearly labeled addition for those who want it, ideally discussed with a physician who has no financial stake in selling it.

References

  1. Waziry R, et al. Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nat Aging. 2023;3(3):248-257.
  2. López-Otín C, et al. Hallmarks of aging: an expanding universe. Cell. 2023;186(2):243-278.
  3. Moqri M, et al. Validation of biomarkers of aging. Nat Med. 2024;30(2):360-372.
  4. Klein EA, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-1177.
  5. Mandsager K, et al. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Netw Open. 2018;1(6):e183605.
Prof. Dr. med. Markus Guba

Head of Liver Surgery and Transplantation at LMU University Hospital Munich. Edits this independent journal in a private capacity; views are his own. About →

This article is general information and not individual medical advice. Decisions about tests and treatment belong in a conversation with your own physician.